3月20日,君实生物(688180/01877)发布公告,近日,公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,注射用JS212的临床试验申请获得批准。该药物主要用于晚期恶性实体瘤的治疗,具有双特异性抗体偶联药物的特性,能够通过与EGFR或HER3结合发挥肿瘤抑制作用,有望对更广泛的肿瘤有效,并克服耐药性问题。根据公告,JS212的临床试验申请于2025年1月8日受理,经过审查符合...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.